KR20230148769A - Food allergy therapy service offer method using oral immunotherapy, computer program recorded in recording medium and system for implementing the same - Google Patents

Abstract

A method of providing food allergy treatment services using oral immunotherapy, and a computer program and system stored in a recording medium for implementing the same are disclosed. For this purpose, the patient information entered in the patient terminal is transmitted to the medical staff terminal connected to the patient terminal through a network, the oral immunotherapy guide information is generated based on the patient information received in the medical staff terminal, and the oral immunotherapy guide information is A step where the symptoms are transmitted to and displayed on the patient terminal, when symptom information about symptoms after protein intake is entered into the patient terminal, the symptom information is transmitted to the medical staff terminal, and the level of adverse reaction is determined by analyzing the symptom information on the medical staff terminal. Provides a method of providing food allergy treatment services that includes steps in which oral immunotherapy guide information is modified according to the reaction grade and transmitted to the patient terminal and displayed. According to the present invention, oral immunotherapy can be performed safely and effectively at home using an app.

Description

Food allergy therapy service offer method using oral immunotherapy, computer program recorded in recording medium and system for implementing the same}

The present invention relates to a method of providing food allergy treatment services using oral immunotherapy, a computer program and a system stored in a recording medium for implementing the same, and more specifically, to a method for safely and effectively inducing desensitization in patients with food allergies. It relates to a method of providing food allergy treatment services that manages the schedule for applying oral immunotherapy, and a computer program and system stored in a recording medium to implement the method.

The prevalence of food allergy in children is 3-5%, and as a result of an epidemiological survey conducted on elementary, middle, and high school students in Korea in 2015, the lifetime prevalence of food allergy symptoms was 15.8%. The prevalence of anaphylaxis, a fatal reaction that can lead to death, has also been reported to be about 1%, which corresponds to 25-30% of all food allergies. The most common allergy-causing foods in children are eggs, milk, and wheat, which account for the majority of all causative foods, and recent reports show that the natural remission period for these allergies is also delayed.

Eggs, milk, wheat, soybeans, peanuts, and walnuts are not only the main sources of nutrition for children, but are also widely included in foods cooked at home or processed foods. As food allergies become older, they are also included in the diet even after entering school. Although restrictions are often necessary, group feeding practices can lead to life-threatening incidents due to unintentional consumption of allergenic foods. In addition, food allergies have a negative impact on children's psychological and physical behavioral development and emotional development through social experiences such as friendships, outdoor activities, and group living, so parents of children and adolescents suffering from food allergies are more likely to raise children than parents of normal children. There are also reports of high stress levels. In particular, eggs, milk, wheat, and soy, which are common causative antigens in children, are used in a wide variety of foods, so the process of restricting diet is very complicated and can lead to nutritional imbalance.

To solve this problem, oral immunotherapy has recently been studied mainly in Western countries, but a unified protocol has not been established. In addition, various oral immunotherapies are being implemented, but they are progressing heterogeneously, raising the need for unified standards for the rate of increase in food antigens, the amount of food antigen proteins taken during the maintenance phase, and evaluation of adverse reactions when they occur. there is. In particular, there is a need for a method to solve the problem of lower compliance and increased anxiety among patients and their guardians due to allergic reactions that frequently occur during the initial dose increase phase of oral immunotherapy and frequent hospital visits resulting from this.

US registered patent US 11,229,673 B2 (2022.01.25.)

Therefore, the purpose of the present invention is to reduce the number of hospital visits and reduce the anxiety of patients and guardians by applying a unified protocol and performing customized oral immunotherapy at home through a smartphone app. Food allergy using oral immunotherapy can be reduced. The goal is to provide a method of providing treatment services, and computer programs and systems stored in a recording medium to implement the same.

In order to achieve the purpose of the present invention described above, the method of providing food allergy treatment service using oral immunotherapy of the present invention is (a) patient information input to the patient terminal is transmitted to the medical staff terminal connected to the patient terminal through a network. step; (b) generating oral immunotherapy guide information based on patient information received at the medical staff terminal; (c) transmitting and displaying the oral immunotherapy guide information to the patient terminal; (d) when symptom information about symptoms after protein intake is entered into the patient terminal, the symptom information is transmitted to the medical staff terminal; (e) analyzing the symptom information at the medical staff terminal to determine the grade of an adverse reaction; and (f) modifying the oral immunotherapy guide information according to the adverse reaction grade and transmitting and displaying it to the patient terminal.

Step (b) includes determining the starting dose of oral immunotherapy with reference to the results of an oral food challenge (OFC) included in the patient information.

In addition, step (b) includes the start date of the oral immunotherapy phase divided into the initial dose increase phase, the dose increase phase, and the maintenance phase, and a food intake schedule that includes a food dose corresponding to the protein dose to be consumed per day. It is characterized as a step in which immunotherapy guide information is generated.

Here, the oral immunotherapy guide information refers to maintaining the starting dose of oral immunotherapy for 1 to 2 weeks in the initial dose increase phase, then increasing the dose by 0.001g each week until it reaches 0.01g based on food antigen protein, and 0.01g. After maintaining for 1 to 2 weeks, increase by 0.01g every week until reaching 0.05g based on food antigen protein, and maintaining for 3 to 7 days when reaching 0.05g, when reaching 0.1g based on food antigen protein It is characterized by including a food intake schedule of increasing the amount by 0.1g for 3 to 7 days.

In addition, the oral immunotherapy guide information is to be consumed daily by increasing the dose equivalent to 3 to 5% of the previous day until it reaches 4g of food antigen protein in the above-mentioned increasing phase when 0.1g of food antigen protein is reached. Choose one of the following food intake schedules: a daily increase schedule that increases the dose by 15 to 25% compared to the previous week, maintains it for one week, and increases the dose by 15 to 25% the next week. It is characterized by including.

In step (c), food corresponding to the protein dose to be consumed per day according to the food intake schedule selected according to the selection command input to any one of the patient terminal and the medical staff terminal among the daily increase schedule and the weekly increase schedule. Preferably, the dose is displayed daily on the patient terminal.

The oral immunotherapy guide information preferably includes a message to visit the hospital because an oral food provocation test is required in the maintenance phase when the food antigen protein standard of 4g is reached.

Here, the oral immunotherapy guide information is characterized in that, if an adverse reaction occurs as a result of the food oral provocation test, the food oral provocation test is re-performed after consuming 2 g to 4 g of food antigen protein daily for 2 months. Do it as

Alternatively, the oral immunotherapy guide information is characterized in that, if no adverse reaction occurs as a result of the food oral provocation test, 4 g of food antigen protein is consumed at least 4 times a week.

The patient information includes the patient's age, gender, underlying disease, medications taken, allergy-causing foods, past disease history, and Oral Food Challenge (OFC) test results.

The oral immunotherapy guide information is characterized in that it is generated to include a food intake schedule that includes a food dose corresponding to the protein dose that must be consumed per day for each of the allergy-causing foods.

The symptom information is characterized in that it includes text information recorded in the patient terminal, image information obtained by photographing the area where the symptom occurs, and voice information recorded by the patient's voice.

Meanwhile, it is a computer program stored in a computer-readable storage medium, the computer program comprising: (a) transmitting patient information input to a patient terminal to a medical staff terminal; (b) generating oral immunotherapy guide information based on patient information received at the medical staff terminal; (c) transmitting and displaying the oral immunotherapy guide information to the patient terminal; (d) when symptom information about symptoms after protein intake is entered into the patient terminal, the symptom information is transmitted to the medical staff terminal; (e) analyzing the symptom information at the medical staff terminal to determine the grade of an adverse reaction; and (f) modifying the oral immunotherapy guide information according to the adverse reaction grade and transmitting and displaying it to the patient terminal.

Here, the patient information is characterized in that it includes at least one of the patient's psychological questionnaire, the guardian's psychological questionnaire, the presence of specific IgE in the patient's blood test, and the results of microbiome analysis.

The method is characterized in that the timing and cycle of the dose increase period among the oral immunotherapy guide information are changed based on the test results of at least one of the patient's psychological questionnaire and the guardian's psychological questionnaire.

The patient's psychological questionnaire and the guardian's psychological questionnaire include at least one of an anxiety and quality of life assessment tool, a depression screening tool, and a resilience scale test.

It is characterized by providing mindset content for psychological stability based on the test results of at least one of the patient's psychological questionnaire and the guardian's psychological questionnaire.

The mindset content is characterized by including educational videos on psychological counseling and oral immunotherapy.

The patient terminal further includes a step of collecting data on similar patients based on the patient's input symptom information and dose increase stage, and the data includes a cheering message and a review of treatment results.

Based on the results of the microbiome analysis, it further includes a step of guiding strain supplementation therapy.

The method of providing food allergy treatment service using oral immunotherapy of the present invention includes the steps of (a) conducting a first survey to confirm the patient's psychological state through a patient terminal and a medical staff terminal connected to the patient terminal through a network; (b) generating oral immunotherapy guide information based on patient information registered in the medical staff terminal and transmitting it to the patient terminal during the initial dose increase period; (c) If the medical staff terminal determines that at least one of anxiety and depression is above the standard as a result of the first survey analysis, the oral immunotherapy guide information is modified to ingest the same amount of protein for a preset period of time. being transmitted to the patient terminal; (d) conducting a second survey to confirm the psychological state through the patient terminal and the medical staff terminal; and (e) when the medical staff terminal determines that the psychological state has not improved as a result of the second survey analysis, the oral immunotherapy guide information is modified and then transmitted to the patient terminal during the dose increase period; It is characterized by including.

In addition, the method of providing food allergy treatment service using oral immunotherapy of the present invention further includes the step of inputting blood and intestinal microbiome test results into the patient terminal and transmitting them to the medical staff terminal, wherein step (e) is characterized by further analyzing the blood and intestinal microbiome test results to determine whether the psychological state has improved.

In step (e), in the increaser stage when 0.1g of food antigen protein is reached, the dose corresponding to 3 to 5% of the previous day is continuously increased every day until it reaches 4g of food antigen protein. The above-mentioned oral immunization was modified so that the weekly dose increase schedule and the weekly increase schedule of increasing the dose corresponding to 15 to 25% of the previous week, maintaining it for one week, and taking the dose corresponding to 15 to 25% again the next week are alternated. It is characterized in that the therapy guide information is transmitted to the patient terminal during the dose increase period.

Alternatively, in step (e), in the increaser phase when 0.1g of food antigen protein is reached, the daily increase schedule continues to increase the dose equivalent to 5% of the previous day's dose every day until it reaches 4g of food antigen protein. The above oral immunotherapy modified by either change to less than 5% if set to be consumed or changed to less than 25% if the weekly dose increase schedule is set to 25% of the previous week until reaching 4g of food antigen protein standard. This step is characterized in that guide information is transmitted to the patient terminal during the dose increase period.

Meanwhile, as a computer program stored in a computer-readable storage medium, the computer program: (a) conducts a first survey to confirm the patient's psychological state through a patient terminal and a medical staff terminal connected to the patient terminal through a network; stage of becoming; (b) generating oral immunotherapy guide information based on patient information registered in the medical staff terminal and transmitting it to the patient terminal during the initial dose increase period; (c) If the medical staff terminal determines that at least one of anxiety and depression is above the standard as a result of the first survey analysis, the oral immunotherapy guide information is modified to ingest the same amount of protein for a preset period of time. being transmitted to the patient terminal; (d) conducting a second survey to confirm the psychological state through the patient terminal and the medical staff terminal; and (e) when the medical staff terminal determines that the psychological state has not improved as a result of the second survey analysis, the oral immunotherapy guide information is modified and then transmitted to the patient terminal during the dose increase period; It is characterized by including instructions for causing the processor to perform.

The food allergy treatment service provision system using oral immunotherapy of the present invention includes a patient terminal into which patient information is input; And a medical staff terminal that receives the patient information transmitted from the patient terminal and generates oral immunotherapy guide information, wherein the patient terminal displays the oral immunotherapy guide information and symptom information about symptoms after protein intake. is input, and the medical staff terminal receives the symptom information transmitted from the patient terminal, analyzes it, determines the adverse reaction grade, modifies the oral immunotherapy guide information according to the adverse reaction grade, and transmits it to the patient terminal. It is characterized by:

In addition, the patient terminal displays question information for the first and second surveys to confirm the psychological state of the patient and guardian, and when answer information for the first and second surveys is entered, Transmitted to the medical staff terminal, the medical staff terminal generates question information for the first and second surveys and transmits it to the patient terminal, and analyzes the answer information transmitted from the patient terminal to the patient and guardian. The oral immunotherapy guide information is modified according to the degree of anxiety or depression and transmitted to the patient terminal.

According to the method of providing food allergy treatment service using oral immunotherapy of the present invention, and the computer program and system stored in a recording medium for implementing the same, the app is used to control food intake at home and monitor side effects, thereby safely and effectively oral treatment at home. Immunotherapy can be performed.

In addition, by dramatically reducing the frequency of allergic reactions and side effects during the initial dose increase period, oral immunotherapy is possible psychologically comfortably, and the number of hospital visits is reduced by developing a food allergy treatment service provision system that can achieve fundamental immune tolerance. It can improve quality of life and reduce medical costs.

Oral immunotherapy can be started at a large hospital under the supervision of a specialist, and can be continued at home or at a primary care institution using an automated food allergy treatment service provision system.

Individually tailored oral immunotherapy guide information can be presented that reflects individual characteristics, including psychological and psychiatric characteristics of food allergy patients and their guardians.

Allergy symptoms that occur during oral immunotherapy can be transmitted as images and voices, automatically interpreted, and messages to deal with adverse reactions can be sent to continue oral immunotherapy efficiently and safely.

Deaths related to school meals can be reduced, and mental stress can be reduced and quality of life deteriorated by ensuring a safe school life.

1 is a block diagram showing the configuration of a food allergy treatment service provision system using oral immunotherapy according to all embodiments of the present invention;
FIGS. 2A to 2D are diagrams for explaining the operation of a patient app running on a patient terminal included in the food allergy treatment service provision system of FIG. 1;
Figures 3A and 3B are diagrams for explaining the operation of the medical staff console running on the medical staff terminal included in the food allergy treatment service provision system of Figure 1;
Figure 4 is a flowchart illustrating a method of providing food allergy treatment services using oral immunotherapy according to an embodiment of the present invention;
Figure 5 is a graph illustrating oral immunotherapy steps in the method of providing food allergy treatment services using oral immunotherapy according to an embodiment of the present invention;
Figure 6 is a flowchart illustrating a method of providing food allergy treatment services using oral immunotherapy according to another embodiment of the present invention.

The features and effects of the present invention described above will become more apparent through the following detailed description in conjunction with the accompanying drawings, and accordingly, those skilled in the art will be able to easily implement the technical idea of the present invention. You will be able to.

Since the present invention can be subject to various changes and have various forms, specific embodiments will be illustrated in the drawings and described in detail in the text. However, this is not intended to limit the present invention to a specific disclosed form, and should be understood to include all changes, equivalents, and substitutes included in the spirit and technical scope of the present invention.

Throughout the specification, when a part is said to 'include' a certain component, this means that, unless specifically stated to the contrary, it does not exclude other components but may further include other components, and one or more components are included. It should be understood that this does not exclude in advance the presence or addition of other features, numbers, steps, operations, components, parts, or combinations thereof.

In this specification, '~ part' is not limited to software or hardware, and '~ part' may be configured to reside in an addressable storage medium or may be configured to reproduce one or more processors. Therefore, as an example, '~ part' refers to components such as software components, object-oriented software components, class components, and task components, processes, functions, properties, and procedures. , subroutines, segments of program code, drivers, firmware, microcode, circuits, data, databases, data structures, tables, arrays, and variables. The functions provided within the components and 'parts' may be combined into a smaller number of components and 'parts' or may be further separated into additional components and 'parts'. Additionally, components and 'parts' may be implemented to regenerate one or more CPUs within a device or a secure multimedia card.

In this specification, some of the operations or functions described as being performed by a terminal, apparatus, or device may instead be performed on a server connected to the terminal, apparatus, or device. Likewise, some of the operations or functions described as being performed by the server may also be performed on a terminal, device, or device connected to the server. Some of the operations or functions described as mapping or matching with the terminal can be interpreted to mean mapping or matching the terminal's unique number or personal identification information, which is the terminal's identifying data. .

Terms such as 'first' and 'second' may be used to describe various components, but the components should not be limited by the terms. The above terms are used only for the purpose of distinguishing one component from another. For example, a first component may be referred to as a second component, and similarly, the second component may also be referred to as a first component without departing from the scope of the present invention.

The term 'at least one or more' is defined as a term that includes singular and plural, and even if the term 'at least one or more' does not exist, each component may exist in singular or plural, and may mean singular or plural. This can be said to be self-evident. In addition, whether each component is provided in singular or plural form may be changed depending on the embodiment.

The terms 'information' and 'data' used throughout the specification may be used interchangeably.

Hereinafter, with reference to the accompanying drawings, a method for providing food allergy treatment services using oral immunotherapy according to a preferred embodiment of the present invention, a computer program and system stored in a recording medium for implementing the same (hereinafter, 'method for providing food allergy treatment services,' ‘Computer program and food allergy treatment service provision system’) is explained in detail.

Figure 1 is a block diagram showing the configuration of a food allergy treatment service provision system using oral immunotherapy according to all embodiments of the present invention.

Referring to Figure 1, the food allergy treatment service provision system of the present invention includes a patient terminal 100 and a medical staff terminal 200, and the patient terminal 100 and medical staff terminal 200 are connected through a wired/wireless network. It transmits and receives signals, data, information, etc.

A wired/wireless network refers to a communication network that supports various communication standards or protocols for pairing or data transmission and reception between the patient terminal 100 and the medical staff terminal 200. These wired/wireless networks include all communication networks that are currently or will be supported in the future according to the standard, and can support one or more communication protocols.

The patient terminal 100 may be implemented as a mobile terminal such as a smart phone, tablet PC, ultrabook, etc. However, it is not limited to this and may also include fixed devices such as personal computers (PCs), microprocessors, mainframe computers, digital processors, and device controllers.

The patient terminal 100 includes a first storage unit 110, a first processor 120, a first communication unit 130, a first display unit 140, a first user interface unit 150, a microphone 160, and Includes a photographing unit 170. Each component may be integrated, added, or omitted depending on the specifications of the patient terminal 100 that is actually implemented. That is, as needed, two or more components may be combined into one component or one component may be subdivided into two or more components. Additionally, the functions performed by each block are for explaining the embodiments of the present disclosure, and the specific operations or devices do not limit the scope of the present invention.

The first storage unit 110 can store data supporting various functions of the patient terminal 100. That is, the first storage unit 110 may store a plurality of application programs running on the patient terminal 100, data for operating the patient terminal 100, commands, and at least one program command. At least some of these application programs may exist on the patient terminal 100 from the time of shipment for the basic functions of the patient terminal 100, or may be downloaded from an external server through wired/wireless communication.

In the present invention, the first storage unit 110 stores the patient app among the computer programs of the present invention, and oral immunotherapy guide information transmitted from the medical staff terminal 200 is stored. In addition, the first storage unit 110 stores information on the amount of protein actually consumed by the patient, the date and time of intake, and symptoms after intake. In addition, when a patient takes drugs or receives injection treatment, information on drug administration history regarding the type and dose of the administered drug is also stored.

The first processor 120 can control the overall operation of the patient terminal 100 and processes signals, data, information, etc. input or output through the components of the patient terminal 100 or the first storage unit 110. ) can provide or process appropriate information or functions by running the application program stored in ). Additionally, the first processor 120 may control at least some of the components of the patient terminal 100 to run an application program stored in the first storage unit 110. Furthermore, the first processor 120 may operate in combination with at least two or more of the components included in the patient terminal 100 to run an application program.

The first processor 120 may be composed of one or more cores and may be any of various commercial processors. For example, the first processor 120 may include a central processing unit (CPU), a general purpose graphics processing unit (GPUGP), a tensor processing unit (TPU), etc. It can be included. Additionally, the first processor 120 may be configured with a dual processor or other multi-processor architecture.

In the present invention, the first processor 120 executes the patient app stored in the first storage unit 110 to display oral immunotherapy guide information through the first display unit 140. In addition, when patient information and symptom information about symptoms after the patient actually consumes protein are entered through the first user interface unit 150, the first processor 120 sends information to the medical staff terminal 200 through the first communication unit 130. ) to be transmitted. The first processor 120 controls the first display unit 140 to display the oral immunotherapy guide information transmitted from the medical staff terminal 200, and allows the patient to chat and make inquiries with the medical staff 24 hours a day through the patient app. Controls data transmission and reception with the medical staff terminal 200.

The first processor 120 causes question information about the first and second surveys to confirm the psychological state of the patient and guardian to be displayed through the first display unit 140, and the first user interface unit 150 ), when the answer information for the first and second surveys is input, it is transmitted to the medical staff terminal 200 through the first communication unit 130.

The first communication unit 130 is one or more modules that enable wired/wireless communication between the patient terminal 100 and a wired/wireless network, between the patient terminal 100 and another device, or between the patient terminal 100 and an external server. may include. Additionally, the first communication unit 130 may include one or more modules that connect the patient terminal 100 to one or more networks. The first communication unit 130 refers to a module for wired/wireless network connection and may be built into or external to the patient terminal 100 and may be configured to transmit and receive wired/wireless signals.

In the present invention, the patient app among the oral immunotherapy management programs is downloaded from an external server through the first communication unit 130. In addition, oral immunotherapy guide information is received from the medical staff terminal 200 through the first communication unit 130, and the patient information entered into the first user interface unit 150, the patient's protein intake dose, intake date and time, and after intake Information on symptoms and drug administration history information on the type and dose of administered drug are transmitted to the medical staff terminal 200.

The first display unit 140 displays various application programs running on the patient terminal 100 on the screen. Oral immunotherapy guide information is provided to the patient through the patient app of the present invention displayed on the first display unit 140. That is, the protein intake dose and intake date according to the oral immunotherapy customized for each patient are displayed through the first display unit 140, and response methods according to symptoms are also displayed through the first display unit 140.

The first user interface unit 150 consists of a keyboard, mouse, touch panel, etc., and receives user commands to control the operation of the patient terminal 100. In the present invention, patient information, the date and time when the patient actually consumed protein, and the intake dose are input through the first user interface unit 150, and symptom information about symptoms after ingestion is input through the first user interface unit 150. is entered.

The microphone 160 is a means of recording the user's voice. When respiratory symptoms occur after protein intake, the patient's voice is recorded, and the recorded voice information is transmitted to the medical staff terminal 200 through the first communication unit 130. .

The imaging unit 170 photographs the patient's skin condition when skin symptoms such as hives occur after protein intake, and the captured image information is transmitted to the medical staff terminal 200 through the first communication unit 130.

Meanwhile, the medical staff terminal 200 of the present invention can be paired or connected to the patient terminal 100 through a wired/wireless network, and can transmit, receive, and display predetermined data through this. The medical staff terminal 200 includes a second storage unit 210, a second processor 220, a second communication unit 230, a second display unit 240, and a second user interface unit 250. Each component may be integrated, added, or omitted depending on the specifications of the medical staff terminal 200 that is actually implemented. That is, as needed, two or more components may be combined into one component or one component may be subdivided into two or more components. Additionally, the functions performed by each block are for explaining the embodiments of the present disclosure, and the specific operations or devices do not limit the scope of the present invention.

The second storage unit 210 can store data supporting various functions of the medical staff terminal 200. That is, the second storage unit 210 may store a plurality of application programs running on the medical staff terminal 200, data for operating the medical staff terminal 200, commands, and at least one program command. At least some of these applications may exist on the medical staff terminal 200 from the time of shipment for the basic functions of the medical staff terminal 200, or may be downloaded from an external server through wired/wireless communication. In the present invention, the second storage unit 210 stores a console for medical staff among the computer programs of the present invention.

The second processor 220 can control the overall operation of the medical staff terminal 200, and processes signals, data, information, etc. input or output through the components of the medical staff terminal 200 or the second storage unit 210. ) can provide or process appropriate information or functions by running the application program stored in ). Additionally, the second processor 220 may control at least some of the components of the medical staff terminal 200 to run the application program stored in the second storage unit 210. Furthermore, the second processor 220 may operate in combination with at least two of the components included in the medical staff terminal 200 to run an application program.

The second processor 220 may be composed of one or more cores and may be any of various commercial processors. For example, the second processor 220 may include a central processing unit (CPU), a general purpose graphics processing unit (GPUGP), a tensor processing unit (TPU), etc. It can be included. Additionally, the second processor 220 may be configured with a dual processor or other multi-processor architecture.

In the present invention, the second processor 220 executes the medical staff console stored in the second storage unit 210 to register patient information, and generates customized oral immunotherapy guide information for each patient based on the registered patient information. In addition, the second processor 220 analyzes the symptom information transmitted from the patient terminal 100 to determine the adverse reaction grade, and modifies the oral immunotherapy guide information according to the adverse reaction grade to be transmitted to the patient terminal 100. do. The second processor 220 controls data transmission and reception with the patient terminal 100 so that the medical staff can chat and consult with the patient 24 hours a day.

The second processor 220 generates question information for the first and second surveys to check the psychological state of the patient and guardian and transmits it to the patient terminal 100 through the first communication unit 130. Then, the response information transmitted from the patient terminal 100 is analyzed to determine the level of anxiety or depression of the patient and guardian, and the oral immunotherapy guide information is modified and transmitted to the patient terminal 100 through the first communication unit 130. Make it possible.

The second communication unit 230 is one or more modules that enable wired/wireless communication between the medical staff terminal 200 and a wired/wireless network, between the medical staff terminal 200 and other devices, or between the medical staff terminal 200 and an external server. may include. Additionally, the second communication unit 230 may include one or more modules that connect the medical staff terminal 200 to one or more networks. The second communication unit 230 refers to a module for wired/wireless network connection and may be built into or external to the medical staff terminal 200 and may be configured to transmit and receive wired/wireless signals.

In the present invention, the patient's protein intake dose, intake date and time, information on symptoms after intake, and drug administration history information regarding the type and dose of the administered drug are received from the patient terminal 100 through the second communication unit 230, Oral immunotherapy guide information is transmitted to the patient terminal 100.

The second display unit 240 displays various application programs running on the medical staff terminal 200 on the screen. Through the medical staff console of the present invention displayed on the second display unit 240, the medical staff can check the date and amount of protein intake by the patient, and check symptoms after intake.

The second user interface unit 250 is composed of a keyboard, mouse, touch panel, etc., and receives user commands to control the operation of the medical staff terminal 200. In the present invention, patient information is registered and modified through the second user interface unit 250, and medical staff commands for creating or modifying oral immunotherapy guide information are input.

FIGS. 2A and 2D are diagrams for explaining the operation of a patient app running on a patient terminal included in the food allergy treatment system of FIG. 1.

FIG. 2A is a diagram illustrating a process for registering patient information through a patient app running on the patient terminal 100. Through the patient app, patients can register basic information such as the patient's name, age, gender, underlying disease, medications, etc., as well as history of allergenic foods and allergic diseases, as well as oral food provocation test (Oral Food). Challenge, OFC) results can also be registered as patient information. Patient information is transmitted to the medical staff terminal 200, and when the medical staff approves registration of the patient information, customized oral immunotherapy guide information is created based on the patient information.

Figures 2b to 2d are diagrams illustrating a process for performing a method of providing food allergy treatment services using oral immunotherapy through a patient app running on the patient terminal 100.

As shown in Figure 2b, oral immunotherapy guide information on intake dosage and precautions for food antigen proteins is provided, and patients Click the 'button to record the intake date and amount of food antigen protein. The protein intake date and amount are stored in the patient terminal 100 and transmitted to the medical staff terminal 200. By selecting each food from today's record, you can check whether or not you have consumed it. If the protein intake date and amount are not received by the medical staff terminal (200) within a certain period of time, the medical staff terminal (200) consumes the food antigen protein and An alarm to record the intake date and dose is generated and transmitted to the patient terminal 100.

As shown in Figure 2c, the symptoms after protein intake and the time at which they occurred are recorded, if skin symptoms such as hives occur, photographs of the area are taken, and if respiratory symptoms occur, audio is recorded. Symptom information about symptoms after ingestion of food antigen protein, such as text information recorded about symptoms, image information taken of the area where symptoms occurred, voice information recorded by the patient's voice, and time when symptoms occurred, are stored in the patient terminal 100. and is transmitted to the medical staff terminal 200.

The medical staff terminal 200 analyzes the received symptom information and determines the grade of adverse reaction. The symptom categories used to determine the grade of adverse reactions are the skin category with symptoms of itching, hives, skin rash, and facial swelling, the conjunctiva category with redness of the eyes, itchy eyes, and watery eyes, the upper respiratory tract category with symptoms of a runny nose and mild cough, and the intermediate category. Alternatively, it is divided into the lower respiratory tract category with symptoms such as severe cough, difficulty breathing, chest tightness, wheezing, and tightness in the throat, the digestive category with symptoms of nausea, abdominal pain, vomiting, and diarrhea, and the circulatory category with symptoms of low blood pressure, decreased consciousness, and cyanosis. .

Adverse reaction grades are classified into mild-moderate-severe or five grades according to CoFAR (Consortium of Food Allergy Research). CoFAR grade 1 is when all symptoms within one of the skin, conjunctiva, upper respiratory tract, and digestive categories are mild. CoFAR grade 2 is when at least one symptom in one of the skin, conjunctiva, upper respiratory tract, and digestive categories is severe, or when symptoms in two or more categories are all mild. CoFAR grade 3 is when there is severe abdominal pain, vomiting/diarrhea more than three times, or all symptoms in the lower respiratory tract category are mild. In this case, the cough is moderate or severe. CoFAR grade 4 is when at least one symptom in the lower respiratory tract category is severe or when there is at least one symptom in the circulatory category. CoFAR level 5 is when death occurs. CoFAR grade 1 can be classified as mild, CoFAR grade 2 is moderate, and CoFAR grade 3 or higher can be classified as severe. Alternatively, CoFAR grade 1 can be classified as mild, CoFAR grade 2-3 can be classified as moderate, and CoFAR grade 4 or higher can be classified as severe.

If it is determined that severe (CoFAR grade 3 or higher) or moderate (CoFAR grade 2) cases have occurred more than twice within a month, a warning message that consultation with medical staff is required through the patient terminal (100) is output. If it is determined to be mild (CoFAR grade 1) or moderate (CoFAR grade 2), a medication guidance message is displayed, as shown in Figure 2d, and after taking the medicine, the type and dose of the drug administered are provided. When medical history information is entered into the patient terminal 100, it is transmitted to the medical staff terminal 200. Accordingly, the modified oral immunotherapy guide information is transmitted from the medical staff terminal 200 to the patient terminal 100 and displayed.

FIGS. 3A and 3B are diagrams for explaining the operation of the medical staff console running on the medical staff terminal 200 included in the food allergy treatment system of FIG. 1.

FIG. 3A is a diagram illustrating a screen on which patient information transmitted from the patient terminal 100 can be confirmed through the medical staff console running on the medical staff terminal 200. Medical staff can check and modify patient information through the medical console. Based on the registered patient information, customized oral immunotherapy guide information is generated as shown in Figure 3b. Medical staff can create and modify oral immunotherapy guide information through the medical staff console.

As illustrated in FIG. 3A, when eggs and milk are selected as foods that cause allergies to the patient, oral immunotherapy guide information including food intake schedules for each of eggs and milk is generated. Referring to Figure 3b, once the starting dose of oral immunotherapy for egg protein is determined and the start date is determined by referring to the food oral provocation test results among the patient information, the oral immunotherapy stages are divided into the initial dose increase phase, dose increase phase, and maintenance phase. The food intake schedule 242 in 241 is generated, respectively.

The initial increase phase is a phase in which the dose is gradually increased by 0.001 to 0.01 g at intervals of 3 to 7 days until it reaches 0.1 g of food antigen protein. The increase phase starts from 0.1g of food antigen protein and increases the food antigen protein by 5% every day or by 25% every week until it reaches 4g. The maintenance phase is the stage in which the amount equivalent to 4g of food antigen protein is consumed once a day, at least 4 times a week. Although not illustrated in FIG. 3B, a dietary restriction period that restricts protein intake after the maintenance period may be further included.

In the food intake schedule 242 for the initial dose increase period illustrated in FIG. 3B, the start date of the initial dose increase period and the intake dose of food antigen protein to be consumed per day are displayed in eight slots 243. The schedule can be modified by deleting the current slot 245 selected from the scheduled intake slots 244 or adding a new slot to the left of the current slot 245. The food intake schedule 242 created in this way is displayed as illustrated in FIG. 2B through the patient app running on the patient terminal 100.

As illustrated in FIGS. 2B to 2D, the intake date, intake dose, symptom information regarding symptoms after intake, and drug administration history information regarding the type and dose of the administered drug are entered into the patient terminal 100 and the medical staff terminal 200. ) and is displayed as a pop-up window 247 in Figure 3b. If the medical staff terminal 200 analyzes symptom information and determines that the adverse reaction grade is moderate (CoFAR grade 2), oral immunotherapy is temporarily suspended (246), as illustrated in FIG. 3B.

If you click pause (246) to restart oral immunotherapy, oral immunotherapy begins from the current slot (245) where it was paused. If the restart date is changed, it restarts from the slot 245 that was paused on the changed date, and if the restart capacity changes, a new step is added below the current step 248 and it restarts from the start date.

Figure 4 is a flowchart illustrating a method of providing food allergy treatment services using oral immunotherapy according to an embodiment of the present invention, and Figure 5 is a flow chart providing food allergy treatment services using oral immunotherapy according to an embodiment of the present invention. This is a graph illustrating the oral immunotherapy steps in the method.

According to Figure 4, first, the patient information entered into the patient terminal 100 is transmitted to the medical staff terminal 200 (S300). Patient information includes at least one of the patient's age, gender, underlying disease, medications taken, allergy-causing foods, past disease history, and Oral Food Challenge (OFC) test results.

Oral immunotherapy guide information is generated based on the patient information received at the medical staff terminal 200 (S310). At this time, the oral immunotherapy guide information is generated to include a food intake schedule that includes the food dose corresponding to the protein dose that must be consumed per day for each allergy-causing food. For example, for a patient who is allergic to eggs or milk, wheat, peanuts, or walnuts, oral immunotherapy guide information including food intake schedules for each egg and milk is created.

In the case of eggs, 100g of egg white contains about 11g of egg protein, and the degree of protein denaturation by heat varies depending on the cooking method. Since soft-boiled eggs are more allergic than hard-boiled eggs, it is safer to use hard-boiled eggs. You can. In the case of milk, 100g of raw milk contains about 3g of milk protein. Unlike raw milk, protein denaturation occurs due to heat, reducing allergenicity, so it may be safer to use warmed milk. In this way, oral immunotherapy guide information may also include information on the form of intake that it is safe to proceed with hard-boiled eggs or warmed milk.

Additionally, when performing oral immunotherapy for two foods, oral immunotherapy guide information is created to ingest one food and then consume the other food at least 2 hours later. If an adverse reaction occurs to one food, oral immunotherapy guide information is created to prevent other foods from being consumed on the same day.

The starting dose of oral immunotherapy is determined by referring to the results of the Oral Food Challenge (OFC) included in the patient information. In other words, depending on the results of the oral food provocation test, the starting dose of oral immunotherapy is determined to be 1/3 to 1/2 of the last dose at which adverse reactions occurred.

Oral immunotherapy guide information includes the start date of the oral immunotherapy stage, which is divided into initial escalation, build up, and maintenance, and the food dose corresponding to the protein dose that should be consumed per day. It is created to include a food intake schedule.

In the initial dose increase phase, the starting dose of oral immunotherapy is maintained for 1 to 2 weeks, then the dose is increased by 0.001g every week until it reaches 0.01g of food antigen protein standard, and when 0.01g is reached, maintained for 1 to 2 weeks, then food Increase the dose by 0.01g every week until it reaches 0.05g based on antigen protein, maintain for 3 to 7 days when 0.05g is reached, and then increase the dose by 0.1g for 3 to 7 days until it reaches 0.1g based on food antigen protein. A food intake schedule is created.

In the initial dose escalation phase, the oral immunotherapy guide includes dosing information to take a leukotriene receptor antagonist (LTRA) daily to reduce the risk of allergic reactions.

The escalation phase, which reaches 0.1 g of food antigen protein, takes at least 22 weeks, and the oral immunotherapy guide information includes dosing information to take the leukotriene receptor antagonist daily if regular medication is taken during the first 2 months of the escalation phase. do.

Leukotriene receptor antagonists can be administered alone or in combination with antihistamines. Additionally, antihistamines may be administered alone to reduce the risk of allergic reactions during the initial dose increase phase and during the dose increase phase.

In the increaser stage, as shown in the graph in (a) of Figure 5, a daily increase schedule is created to continuously increase the dose corresponding to 3 to 5% of the previous day until it reaches 4g of food antigen protein. The daily dose increase schedule is created to increase the dose after confirming that there are no adverse reactions from each dose for at least 1 day, and to consume the same amount without increasing the dose on Fridays and Saturdays. Alternatively, a daily dose increase schedule can be created to increase the dose after confirming that there are no adverse reactions from each dose for at least one day, and also increase the dose on Fridays and Saturdays.

Alternatively, in the increaser stage, as shown in the graph in Figure 5 (b), increase the dose by 20 to 25% compared to the previous week until it reaches 4 g of food antigen protein, maintain it for one week, and then increase it again by 20 to 25% the next week. A weekly increasing schedule may be created to ingest a dose corresponding to . The weekly dose increase schedule is created to increase the dose after confirming that there are no adverse reactions from each dose for at least 7 days.

In the case of the maintenance phase when the food antigen protein standard of 4g is reached, it takes at least one year, and an oral food provocation test is required when the food antigen protein standard of 4g is reached, so a message to visit the hospital will be included in the oral immunotherapy guide information. You can. If an adverse reaction occurs as a result of the food oral provocation test, oral immunotherapy guide information is created to re-perform the food oral provocation test after consuming 2 to 4 g of food antigen protein daily for 2 months. If no adverse reactions occur as a result of the food oral provocation test, oral immunotherapy guide information is created to ingest 4g of food antigen protein once a day, at least 4 times a week.

The oral immunotherapy phase may further include a dietary restriction period to limit protein intake after the maintenance phase. The dietary restriction period is to evaluate whether the patient has reached a “tolerance” that allows for free food intake through oral immunotherapy, and is to check whether the allergy does not reoccur even if the food is not eaten consistently. After the one-month dietary restriction period ends, an oral food provocation test is required, so a message to visit the hospital may be included in the oral immunotherapy guide information. If an adverse reaction occurs as a result of an oral food provocation test, oral immunotherapy guide information is created to ingest 2 to 4 g of food antigen protein at least 4 times for 6 months and then re-perform the same type of oral food provocation test for another month. do. If no adverse reactions occur as a result of the food oral challenge test, oral immunotherapy is terminated.

And oral immunotherapy guide information is transmitted to the patient terminal and displayed (S320). That is, according to the food intake schedule included in the oral immunotherapy guide information, the food dose corresponding to the protein dose to be consumed per day from the start date of the oral immunotherapy stage is displayed on the patient terminal 100 every day, as shown in FIG. 2b. . In the increaser stage, one of the daily increase schedule and the weekly increase schedule is selected according to the selection command input to either the patient terminal 100 or the medical staff terminal 200. The amount of food corresponding to the amount of protein to be consumed per day according to the selected food intake schedule is displayed on the patient terminal 100 every day.

The oral immunotherapy guide information displayed on the patient terminal 100 includes instructions to consume food containing the amount of protein required per day, once a day, at a certain time every day, immediately after a meal, and with medication for allergy symptoms. It also includes a message and instructions to refrain from active movement for two hours after ingestion.

When symptom information about symptoms after protein intake is entered into the patient terminal 100, the symptom information is transmitted to the medical staff terminal 200 (S330). Symptom information includes text information recorded in the patient terminal 100, image information obtained by photographing the area where the symptom occurs, and voice information recorded by the patient's voice. In addition, drug administration history information regarding the amount of protein actually consumed by the patient, intake date and time, type of drug administered, administration time, and dose is also entered into the patient terminal 100 and transmitted to the medical staff terminal 200.

If acute infection symptoms such as fever, vomiting, or diarrhea occur during oral immunotherapy, stop protein intake for 3 days, consume 1/4 of the last intake on the 4th day, and 1/2 of the last intake on the 5th day. The food intake schedule included in the oral immunotherapy guide information is modified to consume the last intake from the 6th day.

The adverse reaction grade is determined by analyzing symptom information at the medical staff terminal 200 (S340). By analyzing the received symptom information, if all the symptoms in one of the skin, conjunctiva, upper respiratory tract, and digestive categories are mild, CoFAR grade 1, if any symptoms in one of the skin, conjunctiva, upper respiratory tract, and digestive categories are severe, If symptoms in two or more categories are mild, it is CoFAR grade 2. If severe abdominal pain or vomiting/diarrhea occurs more than three times, or if all symptoms in the lower respiratory tract category are mild, it is CoFAR grade 3. In this case, the cough is moderate or severe. If any of the symptoms in the lower respiratory tract category are severe, or if any of the symptoms in the circulatory category are severe, it is classified as CoFAR grade 4, and if it leads to death, it is classified as CoFAR grade 5. CoFAR grade 1 can be classified as mild, CoFAR grade 2 is moderate, and CoFAR grade 3 or higher can be classified as severe. Alternatively, CoFAR grade 1 can be classified as mild, CoFAR grade 2-3 can be classified as moderate, and CoFAR grade 4 or higher can be classified as severe.

The oral immunotherapy guide information is modified according to the adverse reaction grade and transmitted to the patient terminal 100 and displayed (S350). If a daily dose increase schedule or a weekly dose increase schedule is selected in the dose escalation phase, the treatment effect is the same, but there are differences in how to respond depending on the grade when adverse reactions occur.

First, when the daily increase schedule is selected, if the adverse reaction is determined to be mild (CoFAR grade 1), take the same amount the next day after taking the antihistamine and confirm that there are no symptoms, then increase protein intake according to the daily increase schedule. The oral therapy guide information is modified and transmitted to the patient terminal 100 and displayed. Here, the oral therapy guide information may be modified to require taking steroids if there is no improvement within 5 to 30 minutes after taking antihistamines.

For example, as shown in [Table 1], if an adverse reaction occurs after consuming 0.105 g of egg protein, the food intake schedule is modified to consume the same 0.105 g the next day and increase the amount the next day if no adverse reaction occurs.

If an adverse reaction occurs with 0.105g of egg protein for 3 days as shown in [Table 2] below, the food intake schedule is modified to increase the amount after confirming that there are no symptoms by consuming 0.105g for 7 days.

Here, if an adverse reaction occurs again when an attempt is made to increase the dose after confirming that there are no symptoms by maintaining the same dose for 7 days, it is defined as a failure to increase the dose. If the failure to increase the dose is repeated more than twice, a warning message is sent to the patient indicating that consultation with a medical staff is necessary. It is transmitted to the terminal 100 and displayed.

If the adverse reaction is judged to be moderate (CoFAR grade 2), after taking antihistamines and steroids together, maintain the dose taken the day before the adverse reaction occurred for 7 days as shown in [Table 3]. The food intake schedule is modified to increase again.

Here, if an adverse reaction occurs again when an attempt is made to increase the dose after confirming that there are no symptoms by maintaining the same dose for 7 days, it is defined as a failure to increase the dose. If the failure to increase the dose is repeated more than twice, a warning message is sent to the patient indicating that consultation with a medical staff is necessary. It is transmitted to the terminal 100 and displayed.

If the adverse reaction is determined to be severe (CoFAR grade 3 or higher), a warning message is sent and displayed on the patient terminal 100 to immediately discontinue oral immunotherapy and consult with a medical staff. In addition, the oral immunotherapy guide information is modified to include antihistamines and steroids, and to use inhaled drugs if present, and is transmitted and displayed on the patient terminal 100.

When the weekly dose increase schedule is selected, if the adverse reaction is determined to be mild (CoFAR grade 1), take the same amount the next day after taking the antihistamine, confirm that there are no symptoms, and then administer oral immunization to increase protein intake according to the weekly dose increase schedule. The therapy guide information is modified and transmitted to the patient terminal 100 and displayed. Here, the oral therapy guide information may be modified to require taking steroids if there is no improvement within 5 to 30 minutes after taking antihistamines.

For example, as shown in [Table 4], if an adverse reaction occurs after consuming 0.125g of egg protein, if the same 0.125g is consumed the next day and no adverse reaction occurs, the adverse reaction will occur after consuming that dose for a total of 7 days. After confirming that this is not done, the food intake schedule is modified to increase the amount.

Here, if an adverse reaction occurs again when an attempt is made to increase the dose after confirming that there are no symptoms by maintaining the same dose for 7 days, it is defined as a failure to increase the dose. If the failure to increase the dose is repeated more than twice, a warning message is sent to the patient indicating that consultation with a medical staff is necessary. It is transmitted to the terminal 100 and displayed.

If an adverse reaction occurs on the 3rd day while consuming 0.125g of egg protein as shown in [Table 5] below, consume 0.125g the next day, confirm that there are no symptoms, and consume 0.125g for a total of 7 days before the adverse reaction occurs. After confirming that this is not done, the food intake schedule is modified to increase the amount.

Here, if an adverse reaction occurs again when an attempt is made to increase the dose after confirming that there are no symptoms by maintaining the same dose for 7 days, it is defined as a failure to increase the dose. If the failure to increase the dose is repeated more than twice, a warning message is sent to the patient indicating that consultation with a medical staff is necessary. It is transmitted to the terminal 100 and displayed.

If the adverse reaction is judged to be moderate (CoFAR grade 2), after taking antihistamine and steroid together, maintain the dose taken the day before the adverse reaction occurred for 7 days as shown in [Table 6]. The food intake schedule is modified to increase again.

Here, if an adverse reaction occurs again when an attempt is made to increase the dose after confirming that there are no symptoms by maintaining the same dose for 7 days, it is defined as a failure to increase the dose. If the failure to increase the dose is repeated more than twice, a warning message is sent to the patient indicating that consultation with a medical staff is necessary. It is transmitted to the terminal 100 and displayed.

If the adverse reaction is determined to be severe (CoFAR grade 3 or higher), a warning message is sent and displayed on the patient terminal 100 to immediately discontinue oral immunotherapy and consult with a medical staff. In addition, the oral immunotherapy guide information is modified to include antihistamines and steroids, and to use inhaled drugs if present, and is transmitted and displayed on the patient terminal 100.

In step S330, the medical staff terminal 200 also receives drug administration history information regarding the amount of food antigen protein consumed by the patient, the date and time of ingestion, the type of drug administered, the time of administration, and the dose, and includes oral immunotherapy guide information. Accordingly, if it is determined that food has not been consumed, a message indicating that oral immunotherapy must be discontinued and consultation with a medical staff is necessary is transmitted and displayed on the patient terminal 100.

Figure 6 is a flowchart illustrating a method of providing food allergy treatment services using oral immunotherapy according to another embodiment of the present invention.

According to Figure 6, first, the patient information entered into the patient terminal 100 is transmitted to the medical staff terminal 200 and registered (S400). Patient information includes at least one of the patient's age, gender, underlying disease, medications taken, allergy-causing foods, past disease history, and Oral Food Challenge (OFC) test results.

According to one embodiment, the patient information may include additional patient test results, including the patient's psychological questionnaire, the guardian's psychological questionnaire, the presence of specific IgE (specific IgE) in the patient's blood test, and the results of the analysis of the intestinal microbiome. . Here, the psychological survey is an anxiety and quality of life assessment tool (e.g., the Korean version of the Beck Anxiety Inventory (K-BAI) and food allergy anxiety - for patients (SOFAA-C or FAAS-C) and for guardians ( SOFAA-P), depression screening tool (e.g., Korean version of depression screening tool PHQ-9), resilience scale test (e.g., Davidson Resilience Scale, K-CD-RISC), Korean Personality Scale for Children Rating Scale for children (KPRC), Food Allergy Quality of Life - Parental Burden, Korean Children's Eating Behavior Questionnaire (K-CEBQ), etc.

The patient terminal 100 may provide guidance by modifying the guide information of the dose increaser or adding a process for providing mindset content for psychological stability, according to the results of the patient's psychological questionnaire and/or the guardian's psychological questionnaire. For example, the mindset content may provide supportive care content such as psychological counseling or educational videos on oral immunotherapy at a specific stage. For example, the supportive care content may include images including images of patients improving the immunity of patients with side effects, and data on the treatment success rate (achieving desensitization) of patients with symptoms similar to the patient. That is, the patient terminal 100 can collect data on similar patients based on the input symptom information. Alternatively, the content may include supportive messages from patients and their guardians who have had similar experiences (allergic reactions, side effects, etc.), and reviews about the success of treatment. In this case, the patient terminal 100 may form content by collecting appropriate data based on patient information, dose increaser stage, etc., among previously collected patient data.

Additionally, based on the results of microbiome analysis, supplementation therapy for deficient strains can be guided.

Additionally, according to one embodiment, guide information for each stage may be provided differently depending on gender and age. For example, if the patient is a boy over 6 years old, additional mindset content can be provided. Alternatively, the input symptom information may be provided to the medical staff terminal 200 and the medical staff terminal 200 may provide additional feedback information to the patient terminal 100.

According to one embodiment, a first survey is conducted to confirm the psychological state of the patient and guardian through the patient terminal 100 and the medical staff terminal 200 (S410). The first survey will be conducted by referring to the Korean version of the depression screening tool (Patient Health Questionnaire-9, PHQ-9). That is, for the first survey, the question information generated in the medical staff terminal 200 is transmitted to the patient terminal 100 by referring to the Korean version of the depression screening tool. And when the answer information for the first survey is entered into the patient terminal 100, it is transmitted to the medical staff terminal 200 and analyzed. The patient terminal 100 can change the timing and cycle of the dose increase phase among the guide information for oral immunotherapy according to the analyzed first survey results.

The patient terminal 100 performs an initial dose increase phase according to oral immunotherapy guide information generated based on patient information (S420). That is, oral immunotherapy guide information is generated based on patient information registered in the medical staff terminal 200 and transmitted to the patient terminal 100 during the initial dose increase period. Oral immunotherapy guide information includes the start date of the oral immunotherapy stage, which is divided into initial escalation, build up, and maintenance, and the food dose corresponding to the protein dose that should be consumed per day. It is created to include a food intake schedule.

At this time, the starting dose of oral immunotherapy is determined by referring to the results of the Oral Food Challenge (OFC) included in the patient information. In other words, depending on the results of the oral food provocation test, the starting dose of oral immunotherapy is determined to be 1/3 to 1/2 of the last dose at which adverse reactions occurred.

Specifically, in the initial dose increase phase, the starting dose of oral immunotherapy is maintained for 1 to 2 weeks, then the dose is increased by 0.001g each week until it reaches 0.01g of the food antigen protein standard, and when 0.01g is reached, it is maintained for 1 to 2 weeks. , increase by 0.01g every week until it reaches 0.05g based on food antigen protein, maintain for 3 to 7 days when 0.05g is reached, and then increase by 0.1g for 3 to 7 days until it reaches 0.1g based on food antigen protein. An increasing food intake schedule is created. In addition, in the initial dose escalation phase, the oral immunotherapy guide information includes dosage information to take a leukotriene receptor antagonist (LTRA) every day to reduce the risk of allergic reactions. Leukotriene receptor antagonists can be administered alone or in combination with antihistamines. Additionally, antihistamines may be administered alone to reduce the risk of allergic reactions during the initial dose increase phase.

As a result of the first survey analysis at the medical staff terminal (200), if anxiety and depression are judged to be below the standard value (S430-N), the protein dose to be consumed during the dose increase period is responded to so that the dose increase period proceeds according to the oral immunotherapy guide information. The food capacity is transmitted to the patient terminal 100 every day and displayed (S440).

The escalation phase, which reaches 0.1 g of food antigen protein, takes at least 22 weeks, and the oral immunotherapy guide includes dosage information requiring leukotriene receptor antagonists to be taken daily even during the first two months of the escalation phase. Leukotriene receptor antagonists can be administered alone or in combination with antihistamines. Additionally, antihistamines may be administered alone to reduce the risk of allergic reactions during the dose increase phase.

In the increaser stage, as shown in the graph in (a) of Figure 5, a daily increase schedule is created to continuously increase the dose corresponding to 3 to 5% of the previous day until it reaches 4g of food antigen protein. The daily dose increase schedule is created to increase the dose after confirming that there are no adverse reactions from each dose for at least 1 day, and to consume the same amount without increasing the dose on Fridays and Saturdays.

Alternatively, in the increaser stage, as shown in the graph in Figure 5 (b), increase the dose by 20 to 25% compared to the previous week until it reaches 4 g of food antigen protein, maintain it for one week, and then increase it again by 20 to 25% the next week. A weekly increasing schedule may be created to ingest a dose corresponding to . The weekly dose increase schedule is created to increase the dose after confirming that there are no adverse reactions from each dose for at least 7 days.

For example, if the medical staff terminal 200 determines that at least one of anxiety and depression is above the standard level as a result of the first survey analysis (S430-Y), the same amount of protein is to be consumed orally for a preset period of time. Immunotherapy guide information is modified and transmitted to the patient terminal 100 (S450). That is, after completing the initial dose increase period, the oral immunotherapy guide information is modified and displayed on the patient terminal 100 to ingest the same dose of protein of 0.1 g for 1 to 2 months without proceeding with the increase period.

In this case, even if there is no symptom information input, guidance may be given not to proceed with the dose increaser.

In addition, in step S450, mind-set content for psychological stability is provided while ingesting the same amount of protein for a preset period of time. In other words, psychological counseling, supportive therapy, watching educational videos, watching videos to improve mindset, etc. are applied to patients and their guardians to help them find psychological stability. And based on the results of microbiome analysis, supplementation therapy for strains lacking in patients is guided. At this time, step-by-step guide information may be provided differently depending on gender and age.

Then, a second survey is conducted to evaluate the psychological state of the patient and guardian (S460). That is, question information for the second survey is generated at the medical staff terminal 200 and transmitted to the patient terminal 100, and when answer information for the second survey is entered into the patient terminal 100, the medical staff terminal ( 200) and analyzed.

The second survey included the Korean version of the Conner-Davidson Resilience Scale (CD-RISC), a tool to measure ego resilience, the Korean version of the Beck Anxiety Inventory (K-BAI), and the Korean Child Personality Assessment. Refer to the Korean Personality Rating Scale for children (KPRC), the Korean Children's Eating Behavior Questionnaire (K-CEBQ), and the Food Allergy Quality of Life - Parental Burden. It proceeds based on the question information generated.

Additionally, in step S460, the patient's blood and intestinal microbiome test results may be input into the medical staff terminal 200 and analyzed along with response information for the second survey. For example, it is advisable to conduct the test 2 to 6 months after starting treatment. The blood test separates serum and measures total IgE (Immunoglobulin E), specific IgE, and IgG4 (Immunoglobulin G4) using ImmunoCAP.

If the medical staff terminal (200) determines that the psychological state has improved as a result of the second survey analysis (S470-Y), the dose corresponding to the protein dose to be consumed during the dose increase period is provided to proceed with the dose increase period according to the oral immunotherapy guide information. The food capacity is transmitted to the patient terminal 100 every day and displayed (S440).

Here, an example is given of using an intestinal microbiome test to evaluate whether the psychological state has improved. However, the intestinal microbiome test is not limited to evaluating whether the psychological state has improved, but can create an immunologically helpful intestinal environment or provide various benefits through this. It can be used to reduce side effects.

On the other hand, if it is determined that the psychological state has not improved (S470-N), the oral immunotherapy guide information is revised and then the dose increase period proceeds (S480). For example, if the escalation phase is set to a daily dose escalation schedule, it is changed to a weekly escalation schedule, and if the escalation phase is set to a weekly escalation schedule, it is changed to a daily escalation schedule, so that the modified oral immunotherapy guide information is maintained during the escalation phase. It is transmitted to the patient terminal 100 and displayed.

Additionally, if it is determined that the psychological state has not improved, content such as the psychological counseling and the educational video may be provided.

Alternatively, in the increaser phase, if the daily increase schedule is set to continuously increase the dose equivalent to 5% of the previous day until it reaches 4g of food antigen protein, reduce it to less than 5% (e.g., 2.5%) , If the weekly dose increase schedule is set at 25% of the previous week until it reaches 4g of food antigen protein standard, it is reduced to less than 25% (e.g., 10%), and the modified oral immunotherapy guide information is displayed on the patient terminal during the dose increase period. It is sent to (100) and displayed.

Then, the maintenance phase proceeds according to the oral immunotherapy guide information (S490). In the case of the maintenance phase when the food antigen protein standard of 4g is reached, it takes at least one year, and an oral food provocation test is required when the food antigen protein standard of 4g is reached, so a message to visit the hospital will be included in the oral immunotherapy guide information. You can. If an adverse reaction occurs as a result of the food oral provocation test, oral immunotherapy guide information is created to re-perform the food oral provocation test after consuming 2 to 4 g of food antigen protein daily for 2 months. If no adverse reactions occur as a result of the food oral provocation test, oral immunotherapy guide information is created to ingest 4g of food antigen protein once a day, at least 4 times a week.

The oral immunotherapy phase may further include a dietary restriction period to limit protein intake after the maintenance phase. The dietary restriction period is to evaluate whether the patient has reached a “tolerance” that allows for free food intake through oral immunotherapy, and is to check whether the allergy does not reoccur even if the food is not eaten consistently. After the one-month dietary restriction period ends, an oral food provocation test is required, so a message to visit the hospital may be included in the oral immunotherapy guide information. If an adverse reaction occurs as a result of an oral food provocation test, oral immunotherapy guide information is created to ingest 2 to 4 g of food antigen protein at least 4 times for 6 months and then re-perform the same type of oral food provocation test for another month. do. If no adverse reactions occur as a result of the food oral challenge test, oral immunotherapy is terminated.

The oral immunotherapy guide information displayed on the patient terminal 100 includes instructions to consume food containing the amount of protein required per day, once a day, at a certain time every day, immediately after a meal, and with medication for allergy symptoms. It also includes a message and instructions to refrain from active movement for two hours after ingestion.

While oral immunotherapy is in progress, when symptom information about symptoms after protein intake is entered into the patient terminal 100, the symptom information is transmitted to the medical staff terminal 200. Symptom information includes text information recorded in the patient terminal 100, image information obtained by photographing the area where the symptom occurs, and voice information recorded by the patient's voice. In addition, drug administration history information regarding the amount of protein actually consumed by the patient, intake date and time, type of drug administered, administration time, and dose is also entered into the patient terminal 100 and transmitted to the medical staff terminal 200.

If acute infection symptoms such as fever, vomiting, or diarrhea occur during oral immunotherapy, stop protein intake for 3 days, consume 1/4 of the last intake on the 4th day, and 1/2 of the last intake on the 5th day. The food intake schedule included in the oral immunotherapy guide information is modified to consume the last intake from the 6th day.

The medical staff terminal 200 analyzes symptom information and determines the grade of adverse reaction. By analyzing the received symptom information, if all the symptoms in one of the skin, conjunctiva, upper respiratory tract, and digestive categories are mild, CoFAR grade 1, if any symptoms in one of the skin, conjunctiva, upper respiratory tract, and digestive categories are severe, If symptoms in two or more categories are mild, it is CoFAR grade 2. If severe abdominal pain or vomiting/diarrhea occurs more than three times, or if all symptoms in the lower respiratory tract category are mild, it is CoFAR grade 3. In this case, the cough is moderate or severe. If any of the symptoms in the lower respiratory tract category are severe, or if any of the symptoms in the circulatory category are severe, it is classified as CoFAR grade 4, and if it leads to death, it is classified as CoFAR grade 5. CoFAR grade 1 is classified as mild, CoFAR grade 2 is moderate, and CoFAR grade 3 or higher is severe. CoFAR grade 1 is classified as mild, CoFAR grade 2-3 is moderate, and CoFAR grade 4 or higher is severe.

The oral immunotherapy guide information is modified according to the adverse reaction grade and is transmitted and displayed on the patient terminal 100. If a daily dose increase schedule or a weekly dose increase schedule is selected in the dose escalation phase, the treatment effect is the same, but there are differences in how to respond depending on the grade when adverse reactions occur.

First, when the daily increase schedule is selected, if the adverse reaction is determined to be mild (CoFAR grade 1), take the same amount the next day after taking the antihistamine and confirm that there are no symptoms, then increase the protein intake according to the daily increase schedule. The oral therapy guide information is modified and transmitted to the patient terminal 100 and displayed. Here, the oral therapy guide information may be modified to require taking steroids if there is no improvement within 5 to 30 minutes after taking antihistamines.

When the weekly dosing schedule is selected, if the adverse reaction is judged to be mild (CoFAR grade 1), take the same amount the next day after taking the antihistamine and confirm that there are no symptoms, then orally increase protein intake according to the weekly dosing schedule. Immunotherapy guide information is modified and transmitted to the patient terminal 100 and displayed. Here, the oral therapy guide information may be modified to require taking steroids if there is no improvement within 5 to 30 minutes after taking antihistamines.

The medical staff terminal 200 also receives drug administration history information regarding the amount of protein the patient actually consumed, date and time of intake, type of drug administered, administration time, and dose, and food intake is not performed according to the oral immunotherapy guide information. If it is determined that this is not the case, a message indicating that oral immunotherapy must be discontinued and consultation with a medical staff is necessary is transmitted and displayed on the patient terminal 100.

Some steps performed in the medical staff terminal 200 may be performed independently in the patient terminal 100, and the patient terminal 100 may modify guide information or modify guide information through data received from the medical staff terminal 200. can be created.

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. For example, each component described as unitary may be implemented in a distributed manner, and similarly, components described as distributed may also be implemented in a combined form.

The scope of the present invention is indicated by the claims described below rather than the detailed description above, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention. do.

100: patient terminal 110: first storage unit
120: first processor 130: first communication unit
140: first display unit 150: first user interface unit
160: Microphone 170: Filming unit
200: medical staff terminal 210: second storage unit
220: second processor 230: second communication unit
240: second display unit 250: second user interface unit

Claims (27)

(a) transmitting patient information input to the patient terminal to a medical staff terminal connected to the patient terminal through a network;
(b) generating oral immunotherapy guide information based on patient information received at the medical staff terminal;
(c) transmitting and displaying the oral immunotherapy guide information to the patient terminal;
(d) when symptom information about symptoms after protein intake is entered into the patient terminal, the symptom information is transmitted to the medical staff terminal;
(e) analyzing the symptom information at the medical staff terminal to determine the grade of an adverse reaction; and
(f) the step of modifying the oral immunotherapy guide information according to the adverse reaction grade and transmitting and displaying it to the patient terminal; A method of providing food allergy treatment service using oral immunotherapy, comprising: According to paragraph 1,
In step (b),
A method of providing food allergy treatment services using oral immunotherapy, comprising the step of determining the starting dose of oral immunotherapy with reference to the results of an oral food challenge (OFC) included in the patient information. According to paragraph 2,
In step (b),
This is the stage in which the oral immunotherapy guide information is generated, including the start date of the oral immunotherapy stage divided into the initial dose increase phase, the dose increase stage, and the maintenance stage, and a food intake schedule including the food dose corresponding to the protein dose to be consumed per day. A method of providing food allergy treatment services using oral immunotherapy, characterized in that: According to paragraph 3,
The oral immunotherapy guide information above is,
In the initial dose increase phase, the starting dose of oral immunotherapy is maintained for 1 to 2 weeks, then increased by 0.001g each week until it reaches 0.01g of the food antigen protein standard, and when 0.01g is reached, maintained for 1 to 2 weeks, Increase by 0.01g every week until reaching 0.05g of food antigen protein, maintain for 3 to 7 days when 0.05g is reached, then increase by 0.1g for 3 to 7 days until reaching 0.1g of food antigen protein. A method of providing food allergy treatment services using oral immunotherapy, comprising a food intake schedule. According to paragraph 3,
The oral immunotherapy guide information above is,
In the above-mentioned increase phase when the food antigen protein standard reaches 0.1g, the daily dose increase schedule is to continuously increase the dose equivalent to 3~5% of the previous day until it reaches 4g food antigen protein standard, and 15% compared to the previous week. Oral immunotherapy, which includes a food intake schedule of one of the weekly increasing schedules in which the dose corresponding to ~25% is increased, maintained for one week, and the dose corresponding to 15 to 25% is consumed again the next week. Method of providing food allergy treatment service. According to clause 5,
In step (c),
The food dose corresponding to the protein dose to be consumed per day according to the food intake schedule selected according to the selection command input to any one of the daily increase schedule and the weekly dose increase schedule in the patient terminal and the medical staff terminal is provided to the patient terminal every day. A method of providing food allergy treatment services using oral immunotherapy, comprising the indicated steps. According to paragraph 3,
The oral immunotherapy guide information above is,
A method of providing food allergy treatment service using oral immunotherapy, characterized in that in the maintenance phase when the food antigen protein standard of 4g is reached, an information message is provided to visit the hospital because an oral food provocation test is necessary. In clause 7,
The oral immunotherapy guide information above is,
If an adverse reaction occurs as a result of the food oral provocation test, food allergy treatment using oral immunotherapy, which is generated to re-perform the food oral provocation test after consuming 2g to 4g of food antigen protein daily for 2 months. How to provide service. In clause 7,
The oral immunotherapy guide information above is,
If no adverse reaction occurs as a result of the food oral provocation test, a method of providing food allergy treatment service using oral immunotherapy, characterized in that 4g of food antigen protein is consumed at least 4 times a week. According to paragraph 1,
The patient information includes the patient's age, gender, underlying disease, medications taken, allergy-causing foods, past disease history, and oral food challenge (OFC) test results. Food allergy using oral immunotherapy How to provide treatment services. According to clause 10,
Providing a food allergy treatment service using oral immunotherapy, wherein the oral immunotherapy guide information is generated to include a food intake schedule that includes a food dose corresponding to the protein dose that must be consumed per day for each of the allergy-causing foods. method. According to paragraph 1,
The symptom information is a method of providing food allergy treatment service using oral immunotherapy, characterized in that it includes text information recorded in the patient terminal, image information obtained by photographing the area where the symptom occurs, and voice information recorded by the patient's voice. A computer program stored in a computer-readable storage medium, the computer program comprising:
(a) transmitting patient information input to the patient terminal to the medical staff terminal;
(b) generating oral immunotherapy guide information based on patient information received at the medical staff terminal;
(c) transmitting and displaying the oral immunotherapy guide information to the patient terminal;
(d) when symptom information about symptoms after protein intake is entered into the patient terminal, the symptom information is transmitted to the medical staff terminal;
(e) analyzing the symptom information at the medical staff terminal to determine the grade of an adverse reaction; and
(f) modifying the oral immunotherapy guide information according to the adverse reaction grade and transmitting and displaying the oral immunotherapy guide information to the patient terminal; A computer program stored on a recording medium for providing information. According to clause 13,
The patient information is a recording medium for providing guide information for oral immunotherapy, characterized in that it includes at least one of the patient's psychological questionnaire, the guardian's psychological questionnaire, the presence of specific IgE in the patient's blood test, and the results of the microbiome analysis. A computer program stored in . The oral immunotherapy method of claim 14, wherein the timing and cycle of the dose increase phase among the oral immunotherapy guide information are changed based on the results of at least one of the patient's psychological questionnaire and the guardian's psychological questionnaire. A computer program stored on a recording medium to provide guide information. The method of claim 15, wherein the patient's psychological questionnaire and the guardian's psychological questionnaire provide guide information for oral immunotherapy, comprising at least one of an anxiety and quality of life assessment tool, a depression screening tool, and a resilience scale test. A computer program stored on a recording medium for providing information. The method of claim 14, wherein mindset content for psychological stability is provided based on test results of at least one of the patient's psychological questionnaire and the guardian's psychological questionnaire. A computer program stored on a recording medium. According to clause 17,
The mindset content is a computer program stored in a recording medium for providing guide information on oral immunotherapy, characterized in that it includes psychological counseling and educational videos on oral immunotherapy. According to clause 18,
The patient terminal further includes the step of collecting data on patients with similar symptoms based on the patient's input symptom information and dose increaser stage,
A computer program stored in a recording medium for providing guide information for oral immunotherapy, wherein the data includes cheering messages and reviews of treatment results. According to clause 14,
A computer program stored in a recording medium, further comprising guiding strain supplementation therapy based on the results of the microbiome analysis. (a) conducting a first survey to confirm the patient's psychological state through a patient terminal and a medical staff terminal connected to the patient terminal through a network;
(b) generating oral immunotherapy guide information based on patient information registered in the medical staff terminal and transmitting it to the patient terminal during the initial dose increase period;
(c) If the medical staff terminal determines that at least one of anxiety and depression is above the standard as a result of the first survey analysis, the oral immunotherapy guide information is modified to ingest the same amount of protein for a preset period of time. being transmitted to the patient terminal;
(d) conducting a second survey to confirm the psychological state through the patient terminal and the medical staff terminal; and
(e) when the medical staff terminal determines that the psychological state has not improved as a result of the second survey analysis, the oral immunotherapy guide information is modified and then transmitted to the patient terminal during the dose increase period; A method of providing food allergy treatment services using oral immunotherapy, comprising: According to clause 21,
It further includes the step of inputting blood and intestinal microbiome test results into the patient terminal and transmitting them to the medical staff terminal,
In step (e),
A method of providing food allergy treatment services using oral immunotherapy, characterized in that the blood and intestinal microbiome test results are further analyzed to determine whether the psychological condition has improved. According to clause 21,
In step (e),
In the above-mentioned increase phase when the food antigen protein standard reaches 0.1g, the daily dose increase schedule is to continuously increase the dose equivalent to 3~5% of the previous day until it reaches 4g food antigen protein standard and 15% compared to the previous week. The oral immunotherapy guide information has been modified so that the weekly dose increase schedule of increasing the dose corresponding to ~25% and maintaining it for one week and taking the dose corresponding to 15 to 25% the next week is alternated. A method of providing food allergy treatment service using oral immunotherapy, characterized in that the step is transmitted to the patient terminal. According to clause 21,
In step (e),
In the above-mentioned increase phase when 0.1g of food antigen protein is reached, the daily increase schedule is set to continue to increase the dose equivalent to 5% of the previous day's dose every day until it reaches 4g of food antigen protein, change to less than 5%. And if the weekly dose increase schedule is set to 25% of the previous week until it reaches 4g of food antigen protein standard, it is changed to less than 25%. A method of providing food allergy treatment service using oral immunotherapy, characterized in that the step is transmitted to a terminal. A computer program stored in a computer-readable storage medium, the computer program comprising:
(a) conducting a first survey to confirm the patient's psychological state through a patient terminal and a medical staff terminal connected to the patient terminal through a network;
(b) generating oral immunotherapy guide information based on patient information registered in the medical staff terminal and transmitting it to the patient terminal during the initial dose increase period;
(c) If the medical staff terminal determines that at least one of anxiety and depression is above the standard as a result of the first survey analysis, the oral immunotherapy guide information is modified to ingest the same amount of protein for a preset period of time. being transmitted to the patient terminal;
(d) conducting a second survey to confirm the psychological state through the patient terminal and the medical staff terminal; and
(e) If the medical staff terminal determines that the psychological state has not improved as a result of the second survey analysis, the oral immunotherapy guide information is modified and transmitted to the patient terminal during the dose increase period; A computer program stored in a recording medium for implementing a method of providing a food allergy treatment service using oral immunotherapy, comprising instructions for a processor to perform. Patient terminal where patient information is input; and
It includes a medical staff terminal that receives the patient information transmitted from the patient terminal and generates oral immunotherapy guide information,
The patient terminal displays the oral immunotherapy guide information, and symptom information about symptoms after protein intake is input,
The medical staff terminal receives the symptom information transmitted from the patient terminal, analyzes it, determines the adverse reaction grade, modifies the oral immunotherapy guide information according to the adverse reaction grade, and transmits it to the patient terminal. Food allergy treatment service provision system using oral immunotherapy. According to clause 26,
The patient terminal is,
Displays question information for the first and second surveys to check the psychological state of the patient and guardian, and transmits the answer information to the medical staff terminal when the answer information for the first and second surveys is entered,
The medical staff terminal is,
Question information for the first and second surveys is generated and transmitted to the patient terminal, and the answer information transmitted from the patient terminal is analyzed to provide the oral immunotherapy guide according to the level of anxiety or depression of the patient and guardian. A food allergy treatment service provision system using oral immunotherapy, characterized in that information is modified and transmitted to the patient terminal.